This study is an open-label, multicenter, proof of concept, phase 2 trial. Patients will be recruited over 18 months. Safety analysis will be performed with a stop of the enrollment after 3 patients have either 1 complete treatment cycle or permanently discontinued treatment whichever occurs first.
Approximatively 65 patients with aggressive large B-cell lymphoma (LBCL) (including diffuse large B-cell lymphoma (DLBCL), Primary mediastinal B-cell lymphoma (PMBCL), any transformed follicular or marginal zone lymphoma, high-grade B-cell lymphoma (HGBL)) will be enrolled in the study.
The duration of treatment with golcadomide (CELMoD) is 24 weeks with 6 cycles of 28 days (4 weeks), starting at 5 days after CAR-T cells infusion.
The primary objective of the study is to estimate the efficacy of golcadomide administered post-anti-CD19 CAR T-cell infusion, Efficacy determination will be based upon the primary endpoint of complete metabolic response (CMR) rate at 3 months after infusion of anti-CD19 CAR T-cell assessed by study investigator.

开始日期2024-06-14

申办/合作机构

Le LYSARC

[+1]

NCT06284122 / Recruiting临床3期IIT

A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma

This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal antibody (mAb) plus chemotherapy in patients with previously untreated FLIPI 2-5 follicular lymphoma.

开始日期2024-06-07

申办/合作机构

Le LYSARC

[+2]

NCT04318080 / Completed临床2期

A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

The primary objective of the study is to evaluate the efficacy of tislelizumab in participants with relapsed/refractory classical Hodgkin lymphoma, as measured by the overall response rate per the Lugano Classification, and as determined by the investigator.

开始日期2020-08-20

申办/合作机构

BeiGene Ltd.

[+1]

100 项与 The Lymphoma Study Association 相关的临床结果

登录后查看更多信息

0 项与 The Lymphoma Study Association 相关的专利（医药）

登录后查看更多信息

项与 The Lymphoma Study Association 相关的文献（医药）

2021-05-01·European Journal of Nuclear Medicine and Molecular Imaging1区 · 医学

Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.

1区 · 医学

Article

作者: Le Gouill, Steven ; Kraeber-Bodéré, Françoise ; Kanoun, Salim ; Jégou, Simon ; Bodet-Milin, Caroline ; Carlier, Thomas ; Casasnovas, René-Olivier ; Berriolo-Riedinger, Alina ; Itti, Emmanuel ; Blanc-Durand, Paul ; Meignan, Michel

PURPOSELymphoma lesion detection and segmentation on whole-body FDG-PET/CT are a challenging task because of the diversity of involved nodes, organs or physiological uptakes. We sought to investigate the performances of a three-dimensional (3D) convolutional neural network (CNN) to automatically segment total metabolic tumour volume (TMTV) in large datasets of patients with diffuse large B cell lymphoma (DLBCL).METHODSThe dataset contained pre-therapy FDG-PET/CT from 733 DLBCL patients of 2 prospective LYmphoma Study Association (LYSA) trials. The first cohort (n = 639) was used for training using a 5-fold cross validation scheme. The second cohort (n = 94) was used for external validation of TMTV predictions. Ground truth masks were manually obtained after a 41% SUVmax adaptive thresholding of lymphoma lesions. A 3D U-net architecture with 2 input channels for PET and CT was trained on patches randomly sampled within PET/CTs with a summed cross entropy and Dice similarity coefficient (DSC) loss. Segmentation performance was assessed by the DSC and Jaccard coefficients. Finally, TMTV predictions were validated on the second independent cohort.RESULTSMean DSC and Jaccard coefficients (± standard deviation) in the validations set were 0.73 ± 0.20 and 0.68 ± 0.21, respectively. An underestimation of mean TMTV by - 12 mL (2.8%) ± 263 was found in the validation sets of the first cohort (P = 0.27). In the second cohort, an underestimation of mean TMTV by - 116 mL (20.8%) ± 425 was statistically significant (P = 0.01).CONCLUSIONOur CNN is a promising tool for automatic detection and segmentation of lymphoma lesions, despite slight underestimation of TMTV. The fully automatic and open-source features of this CNN will allow to increase both dissemination in routine practice and reproducibility of TMTV assessment in lymphoma patients.

2018-04-10·Blood Advances2区 · 医学

Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma

2区 · 医学

Article

作者: van der Gucht, Axel ; Copie-Bergman, Christiane ; Haioun, Corinne ; Delfau-Larue, Marie-Hélène ; Robert, Philippine ; Nel, Isabelle ; Benmaad, Ichrafe ; Jais, Jean-Philippe ; Berriolo-Riedinger, Alina ; Verret, Benjamin ; Itti, Emmanuel ; Beldi-Ferchiou, Asma ; Laboure, Gaelle ; Dupuis, Jehan ; Casasnovas, René-Olivier ; Hamdane, Salma

Key PointsCell-free DNA and circulating tumor cells are related to TMTV in follicular lymphoma at diagnosis. Cell-free DNA levels, in addition to TMTV, define high-risk follicular lymphoma patients.

2017-10-31·Oncotarget

VEGF121, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers

Article

作者: Bernard, Sophie ; Gaulard, Philippe ; Mounier, Nicolas ; Cuccuini, Wendy ; Gisselbrecht, Christian ; Broséus, Julien ; Houlgatte, Rémi ; Thieblemont, Catherine ; Brière, Josette ; Mourah, Samia ; Ramstein, Gérard

Tumor microenvironment including endothelial and immune cells plays a crucial role in tumor progression and has been shown to dramatically influence cancer survival. In this study, we investigated the clinical relevance of the gene expression of key mediators of angiogenesis, VEGF isoforms 121, 165, and 189, and their receptors (VEGFR-1 and R-2) in a cohort of patients (n = 37) with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) from the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL). In patients with ABC-like DLBCL, but not in patients with GCB-like DLBCL, low VEGF₁₂₁ expression was associated with a significantly better survival than in those with high VEGF₁₂₁ level: 4-year overall survival at 100% vs 36% (p = .011), respectively. A specific gene signature including 57 genes was correlated to VEGF₁₂₁ expression level and was analyzed using a discovery process in 1,842 GSE datasets of public microarray studies. This gene signature was significantly expressed in other cancer datasets and was associated with immune response. In conclusion, low VEGF₁₂₁ expression level was significantly associated with a good prognosis in relapsed/refractory ABC-like DLBCL, and with a well-conserved gene-expression profiling signature related to immune response. These findings pave the way for rationalization of drugs targeting immune response in refractory/relapsed ABC-like DLBCL.

100 项与 The Lymphoma Study Association 相关的药物交易

登录后查看更多信息

100 项与 The Lymphoma Study Association 相关的转化医学

登录后查看更多信息